INSULIN-STIMULATED RELEASE OF D-CHIRO-INOSITOL-CONTAINING INOSITOLPHOSPHOGLYCAN

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 胰岛素的某些作用由肌醇磷酸聚糖（IPG）介导。多囊卵巢综合征（PCOS）女性患者中，一种假定的含D-手性肌醇（DCI）IPG介质的释放不足可能导致胰岛素抵抗。以前，我们证明了口服DCI补充剂改善PCOS妇女的排卵和代谢参数。然而，口服DCI是否介导了DCI-IPG介导剂释放的增加以及PCOS女性胰岛素敏感性的改善尚不清楚。我们在11名PCOS患者中进行了一项随机对照试验，比较了DCI补充剂与安慰剂，这些患者在两个时间点间隔6周进行评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Some actions of insulin are mediated by inositolphosphoglycan (IPG) mediators. Deficient release of a putative D-chiro-inositol-containing (DCI) IPG mediator may contribute to insulin resistance in women with polycystic ovary syndrome (PCOS). Previously, we demonstrated that oral DCI supplementation improved ovulation and metabolic parameters in women with PCOS. However, whether oral DCI mediates an increase in the release of the DCI-IPG mediator and an improvement in insulin sensitivity in women with PCOS is unknown. We conducted a randomized controlled trial of DCI supplementation vs placebo in 11 women with PCOS who were assessed at 2 time points 6 weeks apart.